Roth 2000.

Methods	RCT followed by open‐label case series Duration: 14 day RCT plus 12 month case series; total 12.5 months
Participants	N = 133 enrolled in RCT, 106 remained for long‐term follow up Primary condition: Osteoarthritis Baseline pain score: Mean 2.5 (SD 1.2)/3 Likert scale (0 being no pain, 3 being severe pain) Time since onset: Mean 9 years Mean age: 62 years (Range 32 to 90) Female: 73.3% Previous opioid analgesics: Not reported
Interventions	Oral controlled‐release oxycodone Dose: 20 or 40 mg/day, divided Supplemental analgesics: NSAIDS were allowed to continue if dose was stable for 1 month prior to enrolment and not changed during the study. No other analgesics, including opioids or rescue analgesics, were allowed.
Outcomes	Discontinuation due to adverse events Discontinuation due to insufficient pain relief Pain, continuous/categorical
Notes	Both RCT and open‐label continuation are reported on in this citation.
Risk of bias
Bias	Authors' judgement	Support for judgement
Comparability of patients at baseline and follow‐up (continuous data) All outcomes	Unclear risk	Due to attrition
Selection method random or consecutive	Unclear risk	Not reported
Prospective	Low risk	Prospective
Free from confounding treatment(s)	High risk	Use of analgesics other than NSAIDS prohibited
Patient compliance monitored and reported at at least 85%?	Unclear risk	Not reported
Attrition and right censoring less than 15% (continuous data) All outcomes	High risk	Greater attrition
Funding from a source without financial conflict of interest?	High risk	Funding by Perdue Pharma LP